Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 401–500 of 1,000
Treatment of Risk Factors to Prevent Stroke
Aoki, J., & Uchino, K. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0054-0 · Cited by 31
“Ezetimibe reduces LDL cholesterol, and a large-scale trial to study its effects on clinical outcome is ongoing, but to date, it has failed to show any effect on measured atherosclerosis biomarkers [54, 55].”
BackgroundYamazaki, D., Ishida, M., Watanabe, H., Nobori, K., Oguma, Y., Terata, Y., Koyama, T., Iino, K., Kosaka, T., & Ito, H. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-9 · Cited by 27
“The lack of additional benefits of ezetimibe beyond LDL-C and hs-CRP lowering might partly explain the findings of ENHANCE study [44] in which ezetimibe, when added to a statin, did not alter the progression of carotid artery intima-media thickening despite a further reductions in LDL-C and in inflammatory biomarkers…”
van Kuilenburg, J. T., Lappegård, K. T., Sexton, J., Plesiewicz, I., Lap, P., Bouwels, L., Sprong, T., Mollnes, T. E., Verheugt, F. W. A., van Heerde, W. L., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.05.003 · Cited by 27
Squalene Synthase Inhibitor Lapaquistat Acetate: Could Anything Be Better Than Statins?
Liao, J. K. (2011) · Circulation · doi:10.1161/circulationaha.111.028571 · Cited by 26
Ferri, N., Colombo, E., & Corsini, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111371 · Cited by 27
“…ezetimibe, which reduces the intestinal uptake of dietary and biliary cholesterol by inhibiting the Niemann–Pick C1-like protein 1 (NPC1L1) or monoclonal antibodies anti-proprotein convertase subtilisin/kexin type 9 (PCSK9), further reduced the LDL-C levels and major cardiovascular events [3–5].”
Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System
Knapik-Kowalczuk, J., Chmiel, K., Jurkiewicz, K., Correia, N. T., Sawicki, W., & Paluch, M. (2019) · Pharmaceuticals · doi:10.3390/ph12010040 · Cited by 25
“The cornerstone in the prevention of CVDs is lowering high blood cholesterol level [3].”
BackgroundEffects of Ezetimibe on Endothelial Progenitor Cells and Microparticles in High-Risk Patients
Lins, L. C., França, C. N., Fonseca, F. A. H., Barbosa, S. P., de Matos, L. N., Aguirre, A. C. C., Bianco, H. T., do Amaral, J. B., & Izar, M. C. D. O. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-9973-9 · Cited by 25
“Despite the wide use of ezetimibe, an inhibitor of intestinal cholesterol absorption, in clinical practice, the beneficial effect of this lipid-modifying drug on cardiovascular events remains to be demonstrated [5, 6].”
BackgroundLee, S., Park, S., Kang, S., Jang, Y., Chung, N., & Choi, D. (2011) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248411399762 · Cited by 25
Hemphill, L. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.013 · Cited by 25
Dumas, L. S., Briand, F., Clerc, R., Brousseau, E., Montemagno, C., Ahmadi, M., Bacot, S., Soubies, A., Perret, P., Riou, L. M., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177279 · Cited by 26
“Interestingly, ezetimibe in combination with a statin significantly decreased the levels of C-reactive protein and might have metabolic effects other than simply the lowering of LDL cholesterol levels (11,12).”
BackgroundPepine, C. J. (2010) · Annals of Medicine · doi:10.3109/07853890903260898 · Cited by 25
The ezetimibe Jonah: the trials and tribulations of an unlucky drug
Wierzbicki, A. S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02789.x · Cited by 24
Actualización en cardiopatía isquémica
Bardají, A., Barrabés, J. A., Sanchis, J. M., & Sanchez, P. L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70140-8 · Cited by 27
Kawashiri, M., Nohara, A., Higashikata, T., Tada, H., Nakanishi, C., Okada, H., Konno, T., Sakata, K., Hayashi, K., Inazu, A., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.011 · Cited by 24
Treatment of dyslipidemia in the elderly
Hong, S., Li, Q. C., & Xu, J. (2011) · 老年心脏病学杂志:英文版 · doi:10.3724/sp.j.1263.2011.00055 · Cited by 24
Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene
Bea, A. M., Lamíquiz-Moneo, I., Marco-Benedí, V., Mateo‐Gállego, R., Pérez‐Calahorra, S., Jarauta, E., Martín, C., Cenarro, A., & Civeira, F. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.024 · Cited by 25
Castilla‐Guerra, L., Fernández‐Moreno, M. D. C., Jiménez, D. L., & Rico, M. Á. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0563-4 · Cited by 24
Management of Lipid Abnormalities in Patients with Diabetes
Sillars, A., & Sattar, N. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1246-1 · Cited by 24
Luo, P., Li, L., Wang, L. X., Zhu, H., Du, S., Wu, S.-Z., Han, Y., & Wang, G. G. (2014) · Genetics and Molecular Research · doi:10.4238/2014.april.3.10 · Cited by 24
“The ENHANCE group randomized 720 patients with heterozygous hypercholesterolemia into an atorvastatin in combination with ezetimibe group and atorvastatin group, but there was no significant difference in CIMT change between two groups after two-years of treatment (Kastelein et al., 2008).”
MethodSegovia, J., Bermejo, J., & Alfonso, F. (2008) · Revista Española de Cardiología · doi:10.1157/13123994 · Cited by 24
Stein, E. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.002 · Cited by 24
“In addition, when ezetimibe is added to tatin, the “pleiotropic” effects on C-reactive protein, highensity lipoprotein cholesterol (HDL-C), and triglycerides re virtually identical to those of higher dose statin versus ower dose statin (1).”
BackgroundSelf-citationErratum: Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
Agrawal, S., Zaritsky, J. J., Fornoni, A., & Smoyer, W. E. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.175 · Cited by 29
Liu, W., Liu, M., Xiong, H., Xia, L., Yang, Q., Chen, M., Cai, Y., & Li, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109392 · Cited by 24
End Points for Comparative Effectiveness Research in Heart Failure
Allen, L. A., & Spertus, J. A. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.09.002 · Cited by 24
Current Treatment of Familial Hypercholesterolaemia
Lambert, C. T., Sandesara, P. B., Isiadinso, I., Góngora, M. C., Eapen, D. J., Bhatia, N. K., Baer, J., & Sperling, L. S. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.76 · Cited by 24
Warraich, H. J., & Rana, J. S. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1068-6 · Cited by 24
Ma, Y.-B., Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594776 · Cited by 23
“Enhances Atherosclerosis Regression trial (ENHANCE) [70], compared with simvastatin alone, the combined treatment with EXPERT OPINION ON PHARMACOTHERAPY 921”
ResultParhofer, K. G. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0521 · Cited by 24
Management of non-high-density lipoprotein abnormalities
Rosenson, R. S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.020 · Cited by 25
Surrogate outcome markers in research and clinical practice
Twaddell, S. (2009) · Australian Prescriber · doi:10.18773/austprescr.2009.023 · Cited by 23
Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010
Ross, J. S., Frazee, S. G., Garavaglia, S. B., Levin, R., Novshadian, H., Jackevicius, C. A., Stettin, G., & Krumholz, H. M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3404 · Cited by 22
Doğan, S., Duivenvoorden, R., Grobbee, D. E., Kastelein, J. J. P., Shear, C. L., Evans, G. W., Visseren, F. L. J., & Bots, M. L. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.3269 · Cited by 25
Self-citationOh, P. C., Jang, A. Y., Ha, K., Kim, M., Moon, J., Suh, S. Y., Lee, K., Han, S. H., & Kang, W. C. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.05.039 · Cited by 22
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Cesaro, A., Fimiani, F., Gragnano, F., Moscarella, E., Schiavo, A., Vergara, A., Akioyamen, L. E., D’Erasmo, L., Averna, M. R., Arca, M., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.07.008 · Cited by 23
Ezetimibe plus simvastatin for the treatment of hypercholesterolemia
Gryn, S. E., & Hegele, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041504 · Cited by 22
“ENHANCE was a randomized, double-blind, multinational trial that ultimately analyzed 642 patients with familial hypercholesterolemia [43].”
BackgroundResultBlazing, M. A., Giugliano, R. P., de Lemos, J. A., Cannon, C. P., Tonkin, A. M., Ballantyne, C. M., Lewis, B. S., Musliner, T. A., Tershakovec, A. M., Lokhnygina, Y. V., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.004 · Cited by 22
Yamamoto, H., Yamanashi, Y., Takada, T., Mu, S., Tanaka, Y., Komine, T., & Suzuki, H. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115840 · Cited by 22
“…from ezetimibe on atherosclerotic diseases in humans were not observed (intima-media thickness was not improved by ezetimibe administration) (Kastelein et al., 2008; Taylor et al., 2009) or were very limited (only 2% reduction in the rate of cardiovascular events with ezetimibe therapy)…”
BackgroundZoungas, S., Curtis, A. J., McNeil, J. J., & Tonkin, A. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.86 · Cited by 26
Primary Care of the Renal Transplant Patient
Gupta, G., Unruh, M. L., Nolin, T. D., & Hasley, P. B. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1354-5 · Cited by 27
Delles, C., Dymott, J. A., Neisius, U., Rocchiccioli, P., Bryce, G. J., Moreno, M. U., Carty, D., Berg, G. A., Hamilton, C. A., & Dominiczak, A. F. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.01.014 · Cited by 25
Statin and ezetimibe combination therapy in cardiovascular disease
Dembowski, E., & Davidson, M. H. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283295297 · Cited by 24
Vergeer, M., Zhou, R., Bots, M. L., Duivenvoorden, R., Koglin, J., Akdim, F., Mitchel, Y., Huijgen, R., Sapre, A., de Groot, E., et al. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.109.909655 · Cited by 22
Self-citationBiomarkers of Vulnerable Atheromatous Plaques
Wang, X., & Connolly, T. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)50001-5 · Cited by 27
Toth, P. P., Morrone, D., Weintraub, W. S., Hanson, M. E., Lowe, R. S., Lin, J., Shah, A. K., & Tershakovec, A. M. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02964.x · Cited by 21
Gallo, A., Mszar, R., & Miname, M. H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01017-7 · Cited by 21
Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis
Miura, Y., & Suzuki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416224 · Cited by 22
Inhibition of Cholesterol Absorption: Targeting the Intestine
Lee, S. D., Gershkovich, P., Darlington, J. W., & Wasan, K. M. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0858-6 · Cited by 22
Azar, R. R., Badaoui, G., Sarkis, A., Azar, M., Aydanian, H., Harb, S. C., Achkouty, G., & Kassab, R. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.03.016 · Cited by 21
The thyroid receptor β modulator GC-1 reduces atherosclerosis in ApoE deficient mice
Kannisto, K., Rehnmark, S., Slätis, K., Webb, P., Larsson, L., Gåfvels, M. E., Eggertsen, G., & Parini, P. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.035 · Cited by 23
Weir-McCall, J. R., Khan, F., Lambert, M. A., Adamson, C. L., Gardner, M., Gandy, S. J., Ramkumar, P. G., Belch, J. J. F., Struthers, A. D., Rauchhaus, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099190 · Cited by 21
“Additionally while some studies have shown good response of CIMT with statins, the ENHANCE trial showed a rise in CIMT with statins and ezetemide despite improved biochemical markers [3,10].”
ResultAn epidemic of coronary heart disease
Grimes, D. S. (2012) · QJM · doi:10.1093/qjmed/hcr265 · Cited by 23
Faiz, F., Hooper, A. J., & BOCKXMEER, F. M. V. (2012) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.646942 · Cited by 24
Sivapalaratnam, S., van Loendersloot, L. L., Hutten, B. A., Kastelein, J. J. P., Trip, M. D., & de Groot, E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.040 · Cited by 21
Self-citationIndividualized Cardiovascular Risk Assessment By Cardiovascular Magnetic Resonance
Hinojar, R., Botnar, R. M., Kaski, J. C., Prasad, S. K., Nagel, E. C., & Püntmann, V. O. (2014) · Future Cardiology · doi:10.2217/fca.13.102 · Cited by 22
Meershoek, A. J. A., van Dijk, R. A., Verhage, S., Hamming, J. F., van den Bogaerdt, A. J., Bogers, A. J. J. C., Schaapherder, A. F., & Lindeman, J. H. N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.043 · Cited by 22
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt, C. L., & Álvarez, C. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.3.177 · Cited by 23
Malati, T., & Mahesh, M. R. U. (2009) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-009-0063-5 · Cited by 24
Tragante, V., Asselbergs, F. W., Swerdlow, D. I., Palmer, T., Moore, J. H., de Bakker, P. I. W., Keating, B. J., & Holmes, M. V. (2016) · Human Genetics · doi:10.1007/s00439-016-1647-9 · Cited by 22
“Despite the effective lowering of LDL-C by ezetemibe, initial RCTs had not demonstrated its efficacy for surrogate markers of CHD or CHD events (Kastelein et al. 2008; Taylor et al. 2009).”
Winkler, K. E., Schewe, T., Pütz, G., Ödünc, N., Schäfer, G., Siegel, E. G., Geisen, U., Abletshauser, C., & Hoffmann, M. M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02126.x · Cited by 21
Grimes, D. S. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6182-7 · Cited by 21
Doğan, S., Kastelein, J. J. P., Grobbee, D. E., & Bots, M. L. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.8623 · Cited by 21
Self-citationEzetimibe, cardiovascular risk and atherogenic dyslipidaemia
Rizzo, M., & Rini, G. B. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20597 · Cited by 20
“This is supported by findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression, where the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolaemia did not affect the mean change in caro…”
ResultFamilial hypercholesterolaemia
Nair, D. R., Sharifi, M., & Al‐Rasadi, K. (2014) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000083 · Cited by 21
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Snowden, S. G., Grapov, D., Settergren, M., D’Alexandri, F. L., Haeggström, J. Z., Fiehn, O., Hyötyläinen, T., Pedersen, T. L., Newman, J. W. I., Orešič, M., et al. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000606 · Cited by 22
Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia
Bove, M., Fogacci, F., & Cicero, A. F. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1381085 · Cited by 22
“The use of this combination therapy has been in the last decade a great opportunity in clinical practice to reach the LDL target values in a large number [10], especially in subjects at high cardiovascular risk [11,12] or resistant to statin monotherapy, and in some patients with important doserelated statin-associate…”
BackgroundAfter ENHANCE: Is More LDL Cholesterol Lowering Even Better?
Stein, E. A. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.104893 · Cited by 20
Self-citationTarugi, P., Bertolini, S., Calandra, S., Arca, M., Angelico, F., Casula, M., Cefalu, A. B., D’Erasmo, L., Fortunato, G., Filardi, P. P., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.002 · Cited by 20
The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia
Krysiak, R. G., Żmuda, W., & Okopień, B. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00932.x · Cited by 19
Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades
Elis, A., Zhou, R., & Stein, E. A. (2013) · Cardiology in the Young · doi:10.1017/s1047951113000528 · Cited by 19
“Nevertheless, patients in this study were also included in the ENHANCE study, where low baseline carotid intima media thickness levels were reported at enrolment.(36) In conclusion, long-term statin-based therapy provides the opportunity to achieve substantial reduction in low-density lipoprotein cholesterol levels in…”
BackgroundResultSelf-citationToth, P. P., Ballantyne, C. M., Davidson, M. H., Tomassini, J. E., Ramey, D. R., Neff, D., Tershakovec, A. M., Hu, X., & Tunceli, K. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.11.007 · Cited by 19
IMPROVE-IT: what have we learned?
Banach, M., Nikolić, D., Rizzo, M., & Toth, P. P. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000305 · Cited by 22
“The Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE) trial showed no impact on a previously well-accepted surrogate marker of atherosclerosis— carotid intima media thickness (cIMT)—in patients with heterozygous familial hypercholesterolemia [20].”
BackgroundCatapano, A. L., Pirillo, A., & Norata, G. D. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s130338 · Cited by 20
“…lomitapide are registered for patients with homozygous familial hypercholesterolemia (HoFH), while patients with HeFH will benefit from the combination statins/ezetimibe, which yields an additional reduction of 15%–18% 17,18 and, more recently, from the monoclonal antibodies directed against PCSK9.”
Ravnskov, U., de Lorgeril, M., Kendrick, M. E., & Diamond, D. M. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.09.019 · Cited by 20
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
Influence of lipid-lowering drugs on inflammation: what is yet to be done?
Ugovšek, S., Zupan, J., Likozar, A. R., & Šebeštjen, M. (2021) · Archives of Medical Science · doi:10.5114/aoms/133936 · Cited by 21
“The Ezetimibe and Simvastatin in Hypercholesterolaemia Enhances Atherosclerosis Regression (ENHANCE) trial studied the effects of simvastatin and ezetimibe on carotid artery intima-media thickness in patients with familial hypercholesterolaemia [40].”
BackgroundMethodKhera, A. V., & Rader, D. J. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.12.003 · Cited by 19
“Given the recent controversy regarding the benefits of LDL-lowering with ezetimibe (Taylor et al. 2009, Kastelein et al. 2008), it will be of substantial interest to determine whether variants at Niemann-Pick C1-Like 1 (NPC1L1), the drug’s molecular target, are associated with LDL-C levels and CHD.”
BackgroundEmerging antidyslipidemic drugs
Pollex, R. L., JOY, T. R., & Hegele, R. A. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.363 · Cited by 23
“The image captured by the Acuson Aspen ultrasound device with the L7 transducer, comparable to the technology reported in the ENHANCE study [91] .”
BackgroundMethodLuo, P., Wang, L., Zhu, H., Du, S., Wang, G., & Ding, S. (2016) · PubMed · doi:10.6515/acs20151013h · Cited by 19
Ezetimibe: Use, costs, and adverse events in Australia
Hollingworth, S., Ostini, R., David, M., Martin, J. H., & Tett, S. E. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12236 · Cited by 19
“Authority is required for inadequate control with statins (ie, if cholesterol (TC or HDL) does not meet the criteria (which are disease specific) PLUS they have at least one of: (1) coronary heart disease; (2) diabetes; (3) peripheral vascular disease; (4) heterozygous familial hypercholesterolemia; (5) symptomatic ce…”
BackgroundTransporters as Drug Targets: Discovery and Development of NPC1L1 Inhibitors
Betters, J. L., & Yu, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.209 · Cited by 19
Toth, P. P., & Maki, K. C. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.011 · Cited by 19
The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk
Bass, A., Hinderliter, A. L., & Lee, C. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m302 · Cited by 20
Intensive Lipid Intervention in the Post-ENHANCE Era
O’Keefe, J. H., Bybee, K. A., & Lavie, C. J. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60762-3 · Cited by 19
Moyer, M. W. (2010) · Nature Medicine · doi:10.1038/nm0210-150 · Cited by 19
Ciriacks, K., Coly, G., Krishnaswami, S., Patel, S. B., & Kidambi, S. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0114 · Cited by 18
Ibrahim, S., Hartgers, M. L., Reeskamp, L. F., Zuurbier, L. C., Defesche, J. C., Kastelein, J. J. P., Stroes, E. S. G., Hovingh, G. K., & Huijgen, R. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117610 · Cited by 18
Self-citationMicrosomal triglyceride transfer protein inhibition–friend or foe?
JOY, T. R., & Hegele, R. A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1251 · Cited by 18
Lipid Lowering for Secondary Prevention of Cardiovascular Disease in Older Adults
Thomas, J. E., Tershakovec, A. M., Jones-Burton, C., Sayeed, R. A., & Foody, J. M. (2010) · Drugs & Aging · doi:10.2165/11539550-000000000-00000 · Cited by 20
“Age [y; mean (range)] 75 (70–82) 66 (median) [50–97] 63 (40–79) 62 (40–75) 63 (21–92)”
Teramoto, T., Kashiwagi, A., Ishibashi, S., & Daida, H. (2012) · Current Therapeutic Research · doi:10.1016/j.curtheres.2012.02.001 · Cited by 18
Add-On Effect of Probucol in Atherosclerotic, Cholesterol-Fed Rabbits Treated with Atorvastatin
Keyamura, Y., Nagano, C., Kohashi, M., Niimi, M., Nozako, M., Koyama, T., Yasufuku, R., Imaizumi, A., Itabe, H., & Yoshikawa, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096929 · Cited by 20
“tested; however, it remains unclear whether the clinical efficacy of combination therapy is better than that of statin monotherapy [3].”
BackgroundCharland, S. L., & Malone, D. C. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903484802 · Cited by 18
Selective thyroid hormone receptor modulators
Raparti, G., Jain, S., Ramteke, K., Murthy, M., Ghanghas, R. R., Ramanand, S. J., & Ramanand, J. B. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.109663 · Cited by 19
“…have indicated that new drugs such as ezetimibe and torcetrapib, which have novel mechanisms of action, either have not shown an incremental reduction of secondary end points in atherosclerotic disease, such as carotid intima‑media thickness, [17,18] or have had unanticipated adverse effects.”
Pedan, A., & Wu, H. (2011) · Health Marketing Quarterly · doi:10.1080/07359683.2011.545341 · Cited by 18
“This decline, to a large extent, was a consequence of the negative publicity following the publication of the results of the ENHANCE trial (Kastelein et al, 2008 ), which called into question the efficacy of Vytorin (and Zetia) in preventing clinical events.”
ResultMuendlein, A., Leiherer, A., Saely, C. H., Rein, P., Zanolin, D., Kinz, E., Brandtner, E., Fraunberger, P., & Drexel, H. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.011 · Cited by 19
Kishimoto, M., Sugiyama, T., Osame, K., Takarabe, D., Okamoto, M., & Noda, M. (2011) · The Journal of Medical Investigation · doi:10.2152/jmi.58.86 · Cited by 20
Potential therapeutic uses for ezetimibe beyond lowering LDL‐c to decrease cardiovascular events
Ahmed, M. H., & Byrne, C. D. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01261.x · Cited by 18
Statins: Rationale, Mode of Action, and Side Effects
Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Τσούπρας, Α., Kavanagh, E. P., & Hynes, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00006-9 · Cited by 25
Stojaković, T., Campo, A. D., Scharnagl, H., Sourij, H., Schmoelzer, I., Wascher, T. C., & März, W. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02249.x · Cited by 18
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.